Search

Displaying results 4971 - 4980 of 10000 in total
  1. Drug

    Methyl bacteriopurpurinimide

    go.drugbank.com/drugs/DB17134
    Investigational

    Synonyms: 9,12-imino-2,21-metheno-7,4:14,17-dinitrilo-4h-pyrido(4,3-b)azacyclononadecine-16-propanoic acid, 10-(1-butoxyethyl)-19-butyl-5-ethyl-1,5,6,15,16,18,19,20-octahydro-6,11,15,22-tetramethyl-18,20-dioxo-,, 3-(1-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester
  2. Drug

    Iopofosine I-131

    go.drugbank.com/drugs/DB15244
    Investigational

    Iopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).

    Synonyms: 2-((HYDROXY((18-(4-(131I)IODOPHENYL)OCTADECYL)OXY)PHOSPHINYL)OXY)-N,N,NTRIMETHYLETHANAMINIUM INNER SALT, Ethanaminium, 2-((hydroxy((18-(4-(iodo-131I)phenyl)octadecyl)oxy)phosphinyl)oxy)-N,N,N-trimethyl-, inner salt
  3. Drug

    Human immunoglobulin G

    go.drugbank.com/drugs/DB00028
    ApprovedInvestigational

    Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation.

    Categories: Immunoglobulin G, Human Immunoglobulin GSynonyms: Human immunoglobulin G, Immunoglobulin G, human
  4. Drug

    Benzoyl peroxide

    go.drugbank.com/drugs/DB09096
    ApprovedInvestigational

    Benzoyl peroxide is a commonly used drug in topical treatments for acne. … [L33249,L33264,L33269,L33299,L33314] It has been formulated as products with either a single active ingredient,[L33249,L33299] or with [erythromycin],[L33264] [clindamycin],[L33269] or [adapalene].

    Mixtures: OXIMIN 10 MG/G + 50 MG/G JEL,25 G, OXIMIN 10 MG/G + 50 MG/G JEL,50 GSynonyms: Peróxido de benzoilo
  5. Drug

    Treprostinil

    go.drugbank.com/drugs/DB00374
    ApprovedInvestigational

    However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature. … [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life.

    Categories: Prostaglandins I, Cytochrome P-450 SubstratesProducts: TREPROSTINIL DR. REDDY'S, REMODULIN 5 mg/ml Infusionslösung
  6. Drug

    Methionine C-11

    go.drugbank.com/drugs/DB17147
    Investigational

    Synonyms: 2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine, L-(s-methyl-11c)methionine
  7. Drug

    AVR-RD-05

    go.drugbank.com/drugs/DB18631
    Experimental

    AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo_ with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme.

    Synonyms: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
  8. Drug

    Begelomab

    go.drugbank.com/drugs/DB13241
    Investigational

    Begelomab is a murine monoclonal antibody against CD26.

    Synonyms: IMMUNOGLOBULIN G2B-KAPPA, ANTI-(HOMO SAPIENS DPP4(DIPEPTIDYLPEPTIDASE 4, DIPEPTIDYLPEPTIDASE IV, ADENOSINE DEAMINASE COMPLEXING PROTEIN 2, ADCP2, TP103, T CELL ACTIVATION ANTIGEN CD26, CD26)), MUS MUSCULUS
  9. Drug

    Coumaphos

    go.drugbank.com/drugs/DB11390
    ExperimentalVet approved

    This drug is a fat-soluble phosphorothioate agent that kills both insects and mites. It is non-volatile in nature and is well known by a variety of names as such a _dip_ or _wash_.

    Categories: Heterocyclic Compounds, 2-Ring, Heterocyclic Compounds, 1-RingSynonyms: O-(3-chloro-4-methyl-2-oxo-2H-chromen-7-yl) O,O-diethyl thiophosphate, O,O-Diethyl O-(3-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl)phosphorothioate
  10. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. … [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]

    Categories: Heterocyclic Compounds, 2-Ring, Serotonin 5-HT4 Receptor AgonistsProducts: RESOLOR ® TABLETAS RECUBIERTAS DE 2 MG, RESOLOR ® TABLETAS RECUBIERTAS DE 1 MG